KSP logo

KSP

Asia, Kanagawa, Japan, Kawasaki

Description

KSP is the core business entity responsible for operating the Kanagawa Science Park and accepted the challenge of creating new industries.

Investor Profile

KSP has made 6 investments, with 1 in the past 12 months and 0% as lead.

Stage Focus

  • Series Unknown (33%)
  • Series D (17%)
  • Series A (17%)
  • Series B (17%)
  • Seed (17%)

Country Focus

  • Japan (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Health Diagnostics
  • Medical
  • Biopharma
  • Business Development
  • Cloud Computing
  • File Sharing
  • Apps
  • Medical Device
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does KSP frequently co-invest with?

Japan Asia Investment
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
Nissay Capital
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2
Nippon Life Benefits
North America, New York, United States, New York
Co-Investments: 1
Japan Lifeline
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2
Mizuho Capital
Asia, Tokyo, Japan, Tokyo
Co-Investments: 3
Dai-ichi Life
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2
Mitsui Sumitomo Insurance Company
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Mitsubishi UFJ Capital
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
Eight Roads Ventures
Europe, England, United Kingdom, London
Co-Investments: 2

Which angels does KSP often collaborate with?

Yasumasa Manabe
Asia, Tokushima, Japan, Tokushima
Shared Deals: 1

What are some of recent deals done by KSP?

THE PHAGE

Shibuya, Kanagawa, Japan

The phage is a medical device company that focuses on developing AI technology to predict postprandial blood glucose levels.

AppsHealth CareHealth DiagnosticsMedical Device
SeedSep 12, 2024
Metcela

Kawasaki, Kanagawa, Japan

Metcela is a clinical-stage biotech startup providing patients with an alternative treatment option for heart disease.

BiotechnologyHealth CareMedical
Series BJan 4, 2021
Amount Raised: $12,700,000
Miraikikai

Takamatsu, Kagawa, Japan

IMiraikikai's robot products, designed based on field research to provide the high quality and the best cost- effective solution.

Consumer ElectronicsInformation TechnologyManufacturingRobotics
Series UnknownAug 30, 2018
Amount Raised: $6,305,653
Metcela

Kawasaki, Kanagawa, Japan

Metcela is a clinical-stage biotech startup providing patients with an alternative treatment option for heart disease.

BiotechnologyHealth CareMedical
Series AAug 30, 2018
Amount Raised: $4,684,199
Fileforce

Tokyo, Tokyo, Japan

Fileforce provides highly secure and scalable cloud file service for businesses and enterprises of all sizes.

Business DevelopmentCloud ComputingFile Sharing
Series UnknownMay 21, 2015
Amount Raised: $1,006,096
REGiMMUNE

Tokyo, Tokyo, Japan

REGiMMUNE is a biotechnology company producing immune-regulatory therapeutics for life-threatening diseases and debilitating disorders.

BiopharmaBiotechnologyHealth Diagnostics
Series DFeb 14, 2014
Amount Raised: $9,200,000